AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2248835 — intervention group
Group type: COMPARATOR
Intervention: 100% Oxygen
Number of subjects: 8
Study 7023648 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient's history classified according to growth rate
Number of subjects: 756
Study 7023648 — intervention group
Group type: COMPARATOR
Intervention: Other prognostic factors (stage, lymph node status, tumor grade)
Number of subjects: 756
Study 30697661 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 120
Study 30697661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30635940 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60
Study 30635940 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 60
Study 28139938 — intervention group
Group type: EXPERIMENTAL
Intervention: Alt‐RAMEC protocol for 5 weeks (Group 1)
Number of subjects: 34
Study 28139938 — intervention group
Group type: EXPERIMENTAL
Intervention: Alt‐RAMEC protocol for 9 weeks (Group 2)
Number of subjects: 34
Study 28139938 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 34
Study 26536019 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (10 mg/day initially and 20 mg/day at the end of the first week)
Number of subjects: 38
Study 26536019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 23314272 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide/CAF01 vaccine
Number of subjects: 10
Study 23314272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 21980373 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose albendazole (400 mg)
Number of subjects: 314
Study 21980373 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose mebendazole (500 mg)
Number of subjects: 314
Study 21980373 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-dose albendazole (3×400 mg over 3 consecutive days)
Number of subjects: 314
Study 21980373 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-dose mebendazole (3×500 mg over 3 consecutive days)
Number of subjects: 314
Study 21980373 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-dose mebendazole
Number of subjects: 314
Study 21980373 — intervention group
Group type: EXPERIMENTAL
Intervention: Single and triple doses of either drug
Number of subjects: 314
Study 21980373 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-dose regimens
Number of subjects: 314
Study 21980373 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose regimens
Number of subjects: 314
Study 19570098 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dietary supplement containing antioxidants, minerals and glycosaminoglycans
Number of subjects: 60
Study 19570098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18162024 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg q.a.m.
Number of subjects: 647
Study 18162024 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg q.a.m.
Number of subjects: 647
Study 18162024 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg b.i.d.
Number of subjects: 647
Study 18162024 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg q.a.m. (with food)
Number of subjects: 647
Study 18162024 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg b.i.d. (with food)
Number of subjects: 647
Study 18162024 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg q.a.m. (with food)
Number of subjects: 647
Study 18162024 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg q.a.m. without food
Number of subjects: 647
Study 18162024 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg b.i.d. without food
Number of subjects: 647
Study 18162024 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg q.a.m. without food
Number of subjects: 647
Study 15181401 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane administration for 15 min before coronary occlusion
Number of subjects: 42
Study 15181401 — intervention group
Group type: COMPARATOR
Intervention: No sevoflurane administration (Control group)
Number of subjects: 42
Study 11159479 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine hydrochloride 1%
Number of subjects: 25
Study 11159479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9310564 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ondansetron 4 mg
Number of subjects: 11980
Study 9310564 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data from non-duplicated and duplicated reports
Number of subjects: 11980
Study 9310564 — intervention group
Group type: EXPERIMENTAL
Intervention: All original and duplicate reports (n = 25)
Number of subjects: 11980
Study 9310564 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplicated data inclusion in meta-analysis
Number of subjects: 11980
Study 8496205 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple laminotomy (group I)
Number of subjects: 67
Study 8496205 — intervention group
Group type: COMPARATOR
Intervention: Total laminectomy (group III)
Number of subjects: 67
Study 8496205 — intervention group
Group type: COMPARATOR
Intervention: Laminotomy converted to laminectomy (group II)
Number of subjects: 67
Study 3434165 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 58
Study 3434165 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 58
Study 3434165 — intervention group
Group type: COMPARATOR
Intervention: No local treatment
Number of subjects: 58
Study 31837050 — intervention group
Group type: EXPERIMENTAL
Intervention: SM-1
Number of subjects: 39
Study 31837050 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 39
Study 31837050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 28400446 — intervention group
Group type: EXPERIMENTAL
Intervention: Avacopan (30 mg, twice daily) plus reduced-dose prednisone (20 mg daily)
Number of subjects: 67
Study 28400446 — intervention group
Group type: EXPERIMENTAL
Intervention: Avacopan (30 mg, twice daily) without prednisone
Number of subjects: 67
Study 28400446 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus prednisone (60 mg daily)
Number of subjects: 67
Study 25043459 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 µg daily
Number of subjects: 94
Study 25043459 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months
Number of subjects: 94
Study 25043459 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of teriparatide and denosumab
Number of subjects: 94
Study 23549780 — intervention group
Group type: EXPERIMENTAL
Intervention: quasi-volumetric modulated arc therapy (qVMAT)
Number of subjects: 12
Study 23549780 — intervention group
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy (IMRT)
Number of subjects: 12
Study 23549780 — intervention group
Group type: COMPARATOR
Intervention: 3D-conformal radiation therapy (3D-CRT)
Number of subjects: 12
Study 23549780 — intervention group
Group type: EXPERIMENTAL
Intervention: qVMAT with a 0.5 cm ring around the PTV
Number of subjects: 12
Study 23549780 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT with a 0.5 cm ring around the PTV
Number of subjects: 12
Study 21739262 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic duct stenting (S)
Number of subjects: 40
Study 19826986 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative head bandage (61 patients, 73%)
Number of subjects: 84
Study 19826986 — intervention group
Group type: COMPARATOR
Intervention: No head bandage (23 patients, 27%)
Number of subjects: 84
Study 16705561 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional psychological intervention
Number of subjects: 224
Study 16705561 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no additional psychological intervention)
Number of subjects: 224
Study 15650513 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 1182
Study 15650513 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 1182
Study 15650513 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 1182
Study 10666534 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration therapy (60 Hz frequency, 45-min treatment)
Number of subjects: 0
Study 10666534 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (audible hum and lit control box without vibration)
Number of subjects: 0
Study 10666534 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (both vibration and sham)
Number of subjects: 0
Study 10666534 — intervention group
Group type: COMPARATOR
Intervention: Vibration therapy vs. Sham treatment
Number of subjects: 0
Study 9327190 — intervention group
Group type: EXPERIMENTAL
Intervention: etodolac 200 mg
Number of subjects: 40
Study 9327190 — intervention group
Group type: COMPARATOR
Intervention: acetaminophen plus codeine (Tylenol #3)
Number of subjects: 40
Study 8380310 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen pretreatment (2.5 mg of conjugated estrogen, Premarin)
Number of subjects: 73
Study 8380310 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment (control group)
Number of subjects: 73
Study 3533271 — intervention group
Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan (5 mg/kg body weight)
Number of subjects: 21
Study 3533271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 3533271 — intervention group
Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan
Number of subjects: 21
Study 3124899 — intervention group
Group type: COMPARATOR
Intervention: Diet B (fat reduced diet, 35% energy from fat, P:S ratio 0.5)
Number of subjects: 15
Study 3124899 — intervention group
Group type: COMPARATOR
Intervention: Diet C (fat modified diet supplemented with fibre, 27% energy from fat, P:S ratio 1.0)
Number of subjects: 15
Study 3124899 — intervention group
Group type: COMPARATOR
Intervention: Diet A (reference diet, 42% energy from fat, P:S ratio 0.2)
Number of subjects: 15
Study 30943941 — intervention group
Group type: EXPERIMENTAL
Intervention: Free breakfast club intervention
Number of subjects: 318
Study 30943941 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 318
Study 28881387 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin (LF) and lactoperoxidase (LPO) containing tablets
Number of subjects: 46
Study 28881387 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 46
Study 25987323 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment during double-blind trials and a 6-month open-label phase
Number of subjects: 100
Study 25987323 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment
Number of subjects: 100
Study 25987323 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD emotional dysregulation presentation
Number of subjects: 100
Study 25987323 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD inattentive presentation
Number of subjects: 100
Study 25987323 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis
Number of subjects: 100
Study 23242356 — intervention group
Group type: COMPARATOR
Intervention: Harm Avoidance in PD patients
Number of subjects: 43
Study 23242356 — intervention group
Group type: COMPARATOR
Intervention: Novelty Seeking, Reward Dependence, and Persistence in PD patients
Number of subjects: 43
Study 23242356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive flexibility
Number of subjects: 43
Study 23242356 — intervention group
Group type: EXPERIMENTAL
Intervention: Divergent thinking and inhibition
Number of subjects: 43
Study 23242356 — intervention group
Group type: EXPERIMENTAL
Intervention: Novelty Seeking
Number of subjects: 43
Study 21463169 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Interpersonal Therapy (DIT)
Number of subjects: 16
Study 18981043 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated multiple strategies designed to address individual, interpersonal and environmental determinants of physical activity
Number of subjects: 0
Study 16391578 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic visual analogue scale (VAS) system
Number of subjects: 20
Study 16391578 — intervention group
Group type: COMPARATOR
Intervention: Traditional pen and paper version of the questionnaire
Number of subjects: 20
Study 12736118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking for 40 years or more
Number of subjects: 89835
Study 12736118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking of shorter duration
Number of subjects: 89835
Study 12736118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (general)
Number of subjects: 89835
Study 12736118 — intervention group
Group type: COMPARATOR
Intervention: Never-smokers
Number of subjects: 89835
Study 10764905 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory event-related potential (ERP) in PD
Number of subjects: 12
Study 10764905 — intervention group
Group type: COMPARATOR
Intervention: Auditory event-related potential (ERP) in control subjects
Number of subjects: 12
Study 10764905 — intervention group
Group type: EXPERIMENTAL
Intervention: P300 amplitude analysis
Number of subjects: 12
Study 9284855 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (4 micrograms/kg/min) + low-dose furosemide (80 mg/day)
Number of subjects: 20
Study 9284855 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (4 micrograms/kg/min) + medium-dose furosemide (5 mg/kg/day)
Number of subjects: 20
Study 9284855 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose furosemide (10 mg/kg/day)
Number of subjects: 20
Study 8398589 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg orally)
Number of subjects: 9
Study 2945420 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nicorandil
Number of subjects: 11
Study 2945420 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg nicorandil
Number of subjects: 11
Study 2945420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 28400368 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 6763
Study 28400368 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 6763
Study 26285584 — intervention group
Group type: EXPERIMENTAL
Intervention: Met DR 600 mg
Number of subjects: 240
Study 26285584 — intervention group
Group type: EXPERIMENTAL
Intervention: Met DR 800 mg
Number of subjects: 240
Study 26285584 — intervention group
Group type: EXPERIMENTAL
Intervention: Met DR 1,000 mg
Number of subjects: 240
Study 26285584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 26285584 — intervention group
Group type: EXPERIMENTAL
Intervention: Met XR 1,000 mg
Number of subjects: 240
Study 26285584 — intervention group
Group type: EXPERIMENTAL
Intervention: Met XR 2,000 mg
Number of subjects: 240
Study 25198310 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component exercise program
Number of subjects: 0
Study 25198310 — intervention group
Group type: COMPARATOR
Intervention: Calcium and vitamin-D3 intervention
Number of subjects: 0
Study 22377939 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic training
Number of subjects: 16
Study 22377939 — intervention group
Group type: COMPARATOR
Intervention: Normoxic training
Number of subjects: 16
Study 19671306 — intervention group
Group type: EXPERIMENTAL
Intervention: Hp positive group
Number of subjects: 130
Study 18075922 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention package for hazardous drinkers; details on dosage and duration not specified.
Number of subjects: 0
Study 18075922 — intervention group
Group type: COMPARATOR
Intervention: Control condition; details not specified.
Number of subjects: 0
Study 15077240 — intervention group
Group type: EXPERIMENTAL
Intervention: Zydis selegiline 1.25 mg
Number of subjects: 0
Study 15077240 — intervention group
Group type: EXPERIMENTAL
Intervention: Zydis selegiline 2.5 mg
Number of subjects: 0
Study 15077240 — intervention group
Group type: EXPERIMENTAL
Intervention: Zydis selegiline
Number of subjects: 0
Study 15077240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15077240 — intervention group
Group type: COMPARATOR
Intervention: Zydis selegiline and placebo
Number of subjects: 0
Study 12111129 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine
Number of subjects: 13
Study 12111129 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 13
Study 10214575 — intervention group
Group type: EXPERIMENTAL
Intervention: ADCON‐L
Number of subjects: 0
Study 10214575 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 7594015 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer
Number of subjects: 123
Study 7594015 — intervention group
Group type: COMPARATOR
Intervention: Spherical amalgam
Number of subjects: 123
Study 7594015 — intervention group
Group type: COMPARATOR
Intervention: Composite resin
Number of subjects: 123
Study 2375289 — intervention group
Group type: EXPERIMENTAL
Intervention: Strenuous exercise (90 W)
Number of subjects: 18
Study 2375289 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise (30 W)
Number of subjects: 18
Study 7251221 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen treatment (20 mg twice daily for 2 years)
Number of subjects: 270
Study 7251221 — intervention group
Group type: COMPARATOR
Intervention: Postoperative adjuvant radiotherapy or chemotherapy
Number of subjects: 270
Study 7251221 — intervention group
Group type: COMPARATOR
Intervention: ER content levels (high, intermediate, low)
Number of subjects: 270
Study 31481299 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients with bladder cancer
Number of subjects: 24169
Study 31481299 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmuscle-invasive and muscle-invasive bladder cancer subgroups
Number of subjects: 24169
Study 31481299 — intervention group
Group type: COMPARATOR
Intervention: Baseline differences in age, tumor, node, and metastasis-stage and histology
Number of subjects: 24169
Study 28988904 — intervention group
Group type: EXPERIMENTAL
Intervention: Active deep brain stimulation (DBS) targeting bilateral subcallosal cingulate white matter
Number of subjects: 90
Study 28988904 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 90
Study 28988904 — intervention group
Group type: EXPERIMENTAL
Intervention: Active deep brain stimulation (DBS)
Number of subjects: 90
Study 27686349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid restriction protocol
Number of subjects: 151
Study 27686349 — intervention group
Group type: COMPARATOR
Intervention: Standard care protocol
Number of subjects: 151
Study 23834272 — intervention group
Group type: EXPERIMENTAL
Intervention: 78 kPa stress
Number of subjects: 8
Study 23834272 — intervention group
Group type: COMPARATOR
Intervention: 4 kPa stress
Number of subjects: 8
Study 23834272 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 78 kPa and 4 kPa
Number of subjects: 8
Study 23328162 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil (Naf) 50-75 mg once daily for 2 weeks followed by 75 mg once daily for 4 weeks
Number of subjects: 0
Study 23328162 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin (Silo) 2-4 mg twice daily for 2 weeks followed by 4 mg twice daily for 4 weeks
Number of subjects: 0
Study 23328162 — intervention group
Group type: COMPARATOR
Intervention: Silodosin (Silo)
Number of subjects: 0
Study 23328162 — intervention group
Group type: COMPARATOR
Intervention: Naftopidil (Naf)
Number of subjects: 0
Study 23328162 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil (Naf) and Silodosin (Silo)
Number of subjects: 0
Study 19389333 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 100
Study 19389333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17491099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ)
Number of subjects: 61
Study 17491099 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 61
Study 15469803 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral deflazacort (1.5 mg/kg) for 7 days
Number of subjects: 54
Study 15469803 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (1 mg/kg) for 7 days
Number of subjects: 54
Study 11271455 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lens wearers (short-term, intermediate-term, long-term)
Number of subjects: 90
Study 11271455 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lens wearers (more than 6 years)
Number of subjects: 90
Study 11271455 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lens wearers (all subgroups)
Number of subjects: 90
Study 11271455 — intervention group
Group type: COMPARATOR
Intervention: Non-contact lens wearers (control group)
Number of subjects: 90
Study 10399518 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural block (caudal) with 11-15 ml of 2% lidocaine
Number of subjects: 10
Study 10399518 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural catheter insertion
Number of subjects: 10
Study 10399518 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiological study with iohexol contrast medium
Number of subjects: 10
Study 10399518 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia supplementation
Number of subjects: 10
Study 7992812 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 0
Study 7992812 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 2732620 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (2 gm/kg/day)
Number of subjects: 9
Study 31501039 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Automation training
Number of subjects: 40
Study 31501039 — intervention group
Group type: COMPARATOR
Intervention: Traditional training based on face‐to‐face interaction and practical activities
Number of subjects: 40
Study 30362137 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-short implants (≤6 mm)
Number of subjects: 1612
Study 30362137 — intervention group
Group type: COMPARATOR
Intervention: Long implants (≥10 mm)
Number of subjects: 1612
Study 30362137 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1612